With its mission "to make luxurious beauty accessible to all," e.l.f. is on track to post 17% growth in fiscal 2017. The Oakland, Calif.-based firm expects its gains to slow going forward, but leadership remains confident in the business model, which emphasizes speed to market with on-trend innovation at value prices.
The widely reported slowdown in US mass cosmetics may finally be catching up with e.l.f. Beauty, Inc., but the firm continues to expect robust growth for the foreseeable future as it accelerates its mission to provide young, diverse cosmetics enthusiasts with high-quality products at value prices.
The Oakland, Calif.-based company, which went public in September 2016, announced Jan. 8 that it is adjusting its outlook for...
The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
CEO Sue Nabi says Coty has created a “multi-functional, stand-alone organization” within its Consumer Beauty business to drive rapid-fire innovation. In a 20 August presentation, Nabi said the firm’s innovation pipeline undergirds its fiscal 2025 outlook of 6%-8% growth.
The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
